-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Reflux esophagitis is an inflammation of the esophagus, is a common disease of the digestive system, the incidence of nausea and vomiting have heartburn and other symptoms
.
Data show that the incidence of the disease in the general population in China is 6.
4%, so it is of great significance to strengthen the development of drugs for this type of disease
.
At present, the main purpose of the treatment of reflux esophagitis is to relieve symptoms, heal the mucosa and maintain remission of reflux esophagitis, prevent related complications and improve health-related quality of life
.
It is understood that the launch of voronola fumarate green tablets provides a new treatment option for patients with reflux esophagitis
.
The drug blocks the K+ channel of H+, K+-ATPase, competitively blocks the binding of K+ to the enzyme, and can stay in the gastric parietal cells for a long time, thereby quickly inhibiting the secretion of gastric acid
.
Clinical data shows that voronola fumarate raw tablets have the first dose of full effect, long-lasting acid suppression and convenient taking
.
Vonola fumarate was developed by Takeda and launched in Japan in February 2015.
It is used to treat acid-related diseases, including reflux esophagitis, gastric ulcer, duodenal ulcer, and low-dose aspirin.
Or prevent the recurrence of gastric ulcer or duodenal ulcer and eradication of Helicobacter pylori during treatment with non-steroidal anti-inflammatory drugs
.
The Drug Evaluation Center of the National Medical Products Administration officially accepted the listing application of Walker (Vonola Fumarate Green Tablets) in March 2018, and officially approved the listing on December 18, 2019
.
It was approved for marketing in China, providing a new choice for clinical medications for the treatment of reflux esophagitis and greatly improving the quality of life of patients with reflux esophagitis
.
Data show that the incidence of reflux esophagitis in the general population in China is 6.
4%, and the demand for drugs is huge
.
According to statistics, in 2020, the global sales of voronola fumarate green tablets are estimated to exceed US$600 million, while in-hospital sales in China are 2.
83 million
.
In the first half of 2021, voronola fumarate green tablets have achieved 36 million in-hospital sales, which is nearly 13 times the total amount of the previous year, and the demand is very obvious
.
The compound patent of Takeda voronola fumarate green tablets in my country will expire in 2026
.
According to the industry, at present, the development of domestic drugs based on potassium ion competitive acid blocker (P-CAB) can be roughly divided into two categories: one is based on the development of voronola bionics, and the other is based on The development of similar new drugs
.
In terms of generic drugs, on November 15th, Kelun Pharmaceutical reported Takeda Original Research's voronola fumarate green tablets for generic 4 types and was accepted (acceptance number CYHS2102022, CYHS2102023)
.
According to data, Kelun Pharmaceutical was established in 1996 and is a batch of pharmaceutical companies established earlier in China
.
Through continuous strengthening of scientific and technological research and development and investment, it has established the advantages of product clusters in the fields of tumors, parenteral nutrition, bacterial infections and body fluid balance, and has begun to enter the fields of cardiovascular and cerebrovascular, anesthesia and analgesia, diabetes, radiography, hepatitis B and other diseases
.
In addition to Kelun Pharmaceuticals, Shandong New Times and Haihui Pharmaceuticals have also reported the production of the drug in four categories
.
And Shandong New Era, as the first to report for production, may be expected to seize the first imitation
.
At the same time, companies such as Chongqing Watson Pharmaceuticals, Chengdu Kanghong Pharmaceuticals, Yichang Renfu, Yangtze River Pharmaceuticals, Hangzhou Sino-US Huadong Pharmaceuticals, and Chia Tai Tianqing are also conducting BE trials
.
In terms of new drug development, Luoxin Pharmaceutical reached a cooperation agreement with CJ Health Care in 2015, and obtained the latter's P-CAB development, production and commercialization rights in the Chinese mainland for the new drug LXI-15028
.
In addition to Luoxin Pharmaceutical, the X842 jointly developed by Terisino and Ciclus pharma AG of Switzerland and the new drug Konolazan Hydrochloride Tablets of Cofeiping Medicine are currently in phase II clinical trials
.
.
Data show that the incidence of the disease in the general population in China is 6.
4%, so it is of great significance to strengthen the development of drugs for this type of disease
.
At present, the main purpose of the treatment of reflux esophagitis is to relieve symptoms, heal the mucosa and maintain remission of reflux esophagitis, prevent related complications and improve health-related quality of life
.
It is understood that the launch of voronola fumarate green tablets provides a new treatment option for patients with reflux esophagitis
.
The drug blocks the K+ channel of H+, K+-ATPase, competitively blocks the binding of K+ to the enzyme, and can stay in the gastric parietal cells for a long time, thereby quickly inhibiting the secretion of gastric acid
.
Clinical data shows that voronola fumarate raw tablets have the first dose of full effect, long-lasting acid suppression and convenient taking
.
Vonola fumarate was developed by Takeda and launched in Japan in February 2015.
It is used to treat acid-related diseases, including reflux esophagitis, gastric ulcer, duodenal ulcer, and low-dose aspirin.
Or prevent the recurrence of gastric ulcer or duodenal ulcer and eradication of Helicobacter pylori during treatment with non-steroidal anti-inflammatory drugs
.
The Drug Evaluation Center of the National Medical Products Administration officially accepted the listing application of Walker (Vonola Fumarate Green Tablets) in March 2018, and officially approved the listing on December 18, 2019
.
It was approved for marketing in China, providing a new choice for clinical medications for the treatment of reflux esophagitis and greatly improving the quality of life of patients with reflux esophagitis
.
Data show that the incidence of reflux esophagitis in the general population in China is 6.
4%, and the demand for drugs is huge
.
According to statistics, in 2020, the global sales of voronola fumarate green tablets are estimated to exceed US$600 million, while in-hospital sales in China are 2.
83 million
.
In the first half of 2021, voronola fumarate green tablets have achieved 36 million in-hospital sales, which is nearly 13 times the total amount of the previous year, and the demand is very obvious
.
The compound patent of Takeda voronola fumarate green tablets in my country will expire in 2026
.
According to the industry, at present, the development of domestic drugs based on potassium ion competitive acid blocker (P-CAB) can be roughly divided into two categories: one is based on the development of voronola bionics, and the other is based on The development of similar new drugs
.
In terms of generic drugs, on November 15th, Kelun Pharmaceutical reported Takeda Original Research's voronola fumarate green tablets for generic 4 types and was accepted (acceptance number CYHS2102022, CYHS2102023)
.
According to data, Kelun Pharmaceutical was established in 1996 and is a batch of pharmaceutical companies established earlier in China
.
Through continuous strengthening of scientific and technological research and development and investment, it has established the advantages of product clusters in the fields of tumors, parenteral nutrition, bacterial infections and body fluid balance, and has begun to enter the fields of cardiovascular and cerebrovascular, anesthesia and analgesia, diabetes, radiography, hepatitis B and other diseases
.
In addition to Kelun Pharmaceuticals, Shandong New Times and Haihui Pharmaceuticals have also reported the production of the drug in four categories
.
And Shandong New Era, as the first to report for production, may be expected to seize the first imitation
.
At the same time, companies such as Chongqing Watson Pharmaceuticals, Chengdu Kanghong Pharmaceuticals, Yichang Renfu, Yangtze River Pharmaceuticals, Hangzhou Sino-US Huadong Pharmaceuticals, and Chia Tai Tianqing are also conducting BE trials
.
In terms of new drug development, Luoxin Pharmaceutical reached a cooperation agreement with CJ Health Care in 2015, and obtained the latter's P-CAB development, production and commercialization rights in the Chinese mainland for the new drug LXI-15028
.
In addition to Luoxin Pharmaceutical, the X842 jointly developed by Terisino and Ciclus pharma AG of Switzerland and the new drug Konolazan Hydrochloride Tablets of Cofeiping Medicine are currently in phase II clinical trials
.
